AzTrials
AzTrials

Multiple AnomaliesNCT04709965

Evaluating Face-Recognition Technology in Syndrome Diagnosis

A study testing Face2Gene in people with Multiple Anomalies and Dysmorphic Features, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Birth defects are relatively common, occurring in 1 in 40 live born babies. They can be single, or multiple. They may occur as part of multiple malformation syndromes, often in association with growth disturbance or intellectual disability. Over 7000 rare syndromes have been identified. Read more about this study

Who is it for?
Ages 8 months and older
What is being tested?
Face2Gene
Could I receive a placebo?
No, everyone receives an active treatment
How many people
111 participants
Where
1 siteUnited Kingdom
Study dates
30 Jan 2018to 25 Nov 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 months and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
  • OR:
  • Biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder

Who cannot join

  • Patients under 8 months of age where face-recognition technology has not been shown to be effective.
  • Patients who decline clinical photography as part of standard care.
  • Patients who do not wish to consent to participation in the study even though they consent to photos being taken for standard care.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Manchester University NHS Foundation Trust

    Manchester, Greater Manchester, M13 9WL

Other trials in United Kingdom

About this study

Official title: Evaluating the Clinical Utility of Face-Recognition Technology in Syndrome Diagnosis

Birth defects are relatively common, occurring in 1 in 40 live born babies. They can be single, or multiple. They may occur as part of multiple malformation syndromes, often in association with growth disturbance or intellectual disability. Over 7000 rare syndromes have been identified. Thus, though they are rare they are collectively important. Understanding how a multiple malformation syndrome came about, defining what investigations and health surveillance is needed for affected children and identifying whether there is a treatment is very important for parents and professionals caring for affected children and also for genetic counselling of their extended families, since the majority will have a genetic basis. Diagnosis of these rare disorders is therefore important,but as many syndromes are rare this can be extremely difficult and requires specialist knowledge, many investigations and many hospital appointments. This study aims to determine whether using face-recognition software can improve diagnosis of rare syndromes when used in addition to current routine practice.

Read the detailed description

Clinicians see over 2000 patients per year who have rare syndromes in Manchester NHS clinics. In the majority of these individuals the cause is unknown. Many will have a genetic cause, but knowing which genes to test and being able to access these tests is difficult. When a patient comes to the clinic, details of their medical and developmental history are collected , and they are examined in detail to look at their investigation results. New tests may also be ordered for patients. In many cases, subtle differences in physical features, especially facial features may provide an important clue to the underlying diagnosis. However, because many of the conditions seen are so rare and doctors may not have seen that particular condition before, the diagnosis may not be made immediately at the appointment. In those cases, permission will be sought to take photographs so that further opinions can be sought within the department or by sharing with national and sometimes international colleagues. This is routine practice. Where consent has been obtained for photos, these are then first reviewed in a departmental case-review meeting. They may then also be presented at regional, national or even international meetings aimed at syndrome diagnosis with patient consent.

The study aims to recruit patients who are attending clinics for syndrome diagnosis, and who have differences in their facial features. Such patients will undergo a full routine diagnostic work-up as outlined above. Following that, if patients have consented to having photographs taken as part of standard care, they will be asked if they would consent to upload of the facial photographs to a digital face recognition system, along with upload of a list of key clinical features, to see which diagnoses are suggested by this software.

A group of Inherited Metabolic Disease patients with known diagnoses will be included under the Faces sub-study to establish whether the technology may help to define their phenotype. This group of patients would be asked to send photos to the research team either by email via a secure email address or by post. The study would request one facial photo of each of the biological parents (where applicable and available).

There will first of all be routine discussion of patients and photographs in a case review meeting as per standard practice. Differential diagnoses will be formulated and recorded based on this. Following this, the facial photo will be uploaded to a face recognition system and suggested diagnoses from this recorded. Any diagnostic suggestions considered worthy of investigation will be followed up in line with standard practice.

The investigators will then determine whether this was made a) in the standard way b) only suggested by the face recognition software or c) utilising the two methods together.

Patients will be followed up to see if a final diagnosis is confirmed. The patient/parents will also be sent a questionnaire by email or post 6 months after recruitment. The questionnaire will ask if they had any concerns about using FDNA, if they found it helpful and if so in what way. Another questionnaire to professionals will collect information on how easy they found it to use, how helpful they found it ranging 1-5, did it alter patient management, if so how, and other comments

. The investigators will document whether utilising the software helped to arrive at an earlier diagnosis, whether it impeded the diagnosis by providing misleading or incorrect guidance, whether parents and professionals found its use acceptable and whether it impacted on the patient's management.

Being tested
Face2Gene
Medical subject headings
Abnormalities, Multiple, Metabolism, Inborn Errors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Face2GeneDiagnostic test

    This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.

Study groups in NCT04709965
Study groupRoleWhat they receive
Main StudyOtherPatients attending routine genetic clinic/paediatric clinic appointments for diagnosis of a multiple anomaly syndrome where distinctive facial features form part of their presenting pattern.
Receives: Diagnostic Test: Face2Gene
Faces Sub StudyOtherPatients eligible to be recruited to the Faces Sub Study will have biochemically or genetically confirmed diagnosis of inborn disorder of metabolism where no well described dysmorphic facial features are known to be associated with disorder.
Receives: Diagnostic Test: Face2Gene

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of diagnoses

    The number of diagnoses of rare syndrome disorders made, measured after standard practice

    Measured: through study completion, an average of 2 years

  2. Number of diagnoses

    The number of diagnoses of rare syndrome disorders made, Measured after use of the Face2Gene app

    Measured: through study completion, an average of 2 years

Secondary outcomes (3)
  1. Patient satisfaction

    Level of satisfaction of parents with use of a face recognition system and with e-health approaches to genetic counselling and diagnosis in general. Measured via a patient experiences questionnaire that requires both quantitative and qualitative responses. The proportion of patients who found use of the software acceptable will be measured. There results will not be reported on a fixed scale.

    Measured: 6 months after recruitment.

  2. Professional satisfaction

    Level of satisfaction of professionals with use of a face recognition system. Measured via a colleagues experiences questionnaire that requires both quantitative and qualitative responses. The proportion of professionals who found using the software acceptable/helpful and would continue using the software in practice will be measured. There results will not be reported on a fixed scale.

    Measured: 24 months

  3. Number of syndromes

    Number of syndromes identified where face recognition software has facilitated genetic investigation.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jan 2021
  2. Study start30 Jan 2018
  3. Primary completion25 Nov 2020
  4. Study completion25 Nov 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
111 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04709965
Sponsor's protocol ID
R04765
Status last verified
Jan 2021
First submitted
3 Dec 2020
Last updated
14 Jan 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Face2Gene in people with Multiple Anomalies and Dysmorphic Features, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of diagnoses (time frame: through study completion, an average of 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in